Breaking News

Integra LifeSciences issued the following statement regarding the FDA safety communication on the differences in complication rates between acellular dermal matrix, or ADM, products used in implant-based breast reconstruction: "Integra LifeSciences supports the efforts of the U.S. FDA to protect women's health, including its recent safety communication on ADM products used in implant-based breast reconstruction. SurgiMend Collagen Matrix is currently cleared by the FDA for use in certain types of surgeries to reinforce tissue where weakness exists, such as plastic and reconstructive surgery, and hernia repair. Neither SurgiMend nor any other ADM (human or xenograft) is currently approved for use in breast reconstruction in the United States. It is important for patients to discuss the use of medical technologies, including SurgiMend, with their healthcare providers. Integra is committed to delivering safe and effective medical technologies and products to our customers and their patients, including securing clearance or approval for a product indicated for breast reconstruction. We work to consistently meet or exceed industry and global regulatory standards to provide quality products and technologies designed to meet the needs of our customers and their patients. We applaud the ongoing work of the various surgeon associations and patient advocacy groups in reinforcing the importance of quality patient care and promoting education, advocacy, and public awareness of various healthcare issues. Integra continues to collaborate with the clinical community to pursue solutions to advance women's health."

SS&C announced that the board of directors of Mainstream Group has unanimously recommended an acquisition by SS&C of 100% of the shares and outstanding equity rights in Mainstream for A$2.00 per security pursuant to a scheme of arrangement. The matching rights of Vistra Group in connection with its prior Scheme Implementation Deed have now expired and Mainstream is proceeding to terminate that agreement with Vistra Group in accordance with its terms. SS&C's Scheme Implementation Deed will then become fully operative per its terms. Mainstream is a provider of investment administration, middle office, fund accounting, superannuation administration, share registry and unit registry services to fund managers and superannuation funds, family offices and dealer groups. The company serves clients globally through its offices in Australia, Hong Kong, Singapore, Ireland, Malta, Isle of Man, the Cayman Islands and the U.S. Terms of the proposed acquisition imply an enterprise value for Mainstream of approximately A$296M or approximately $225M. The purchase is expected to close in Q3.

Synnex (SNX) announced a new distribution agreement with Citrix (CTXS). Under the terms of agreement, Synnex will provide their partner community with access to Citrix digital workspace solutions. The solutions will immediately be available to partners in the U.S. and Canada through Synnex Stellr.